TY - JOUR
T1 - Alternating hemiplegia of childhood
T2 - Retrospective genetic study and genotype-phenotype correlations in 187 subjects from the US AHCF registry
AU - Viollet, Louis
AU - Glusman, Gustavo
AU - Murphy, Kelley J.
AU - Newcomb, Tara M.
AU - Reyna, Sandra P.
AU - Sweney, Matthew
AU - Nelson, Benjamin
AU - Andermann, Frederick
AU - Andermann, Eva
AU - Acsadi, Gyula
AU - Barbano, Richard L.
AU - Brown, Candida
AU - Brunkow, Mary E.
AU - Chugani, Harry T.
AU - Cheyette, Sarah R.
AU - Collins, Abigail
AU - DeBrosse, Suzanne D.
AU - Galas, David
AU - Friedman, Jennifer
AU - Hood, Lee
AU - Huff, Chad
AU - Jorde, Lynn B.
AU - King, Mary D.
AU - LaSalle, Bernie
AU - Leventer, Richard J.
AU - Lewelt, Aga J.
AU - Massart, Mylynda B.
AU - Mérida, Mario R.
AU - Ptáček, Louis J.
AU - Roach, Jared C.
AU - Rust, Robert S.
AU - Renault, Francis
AU - Sanger, Terry D.
AU - De Menezes, Marcio A.Sotero
AU - Tennyson, Rachel
AU - Uldall, Peter
AU - Zhang, Yue
AU - Zupanc, Mary
AU - Xin, Winnie
AU - Silver, Kenneth
AU - Swoboda, Kathryn J.
N1 - Publisher Copyright:
© 2015 Viollet et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/5/21
Y1 - 2015/5/21
N2 - Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase. Published studies to date indicate 2 recurrent mutations, D801N and E815K, and a more severe phenotype in the E815K cohort. We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012. Clinical data were abstracted from standardized caregivers' questionnaires and medical records and confirmed by expert clinicians. We identified ATP1A3 mutations by Sanger and whole genome sequencing, and compared phenotypes within and between 4 groups of subjects, those with D801N, E815K, other ATP1A3 or no ATP1A3 mutations. We identified heterozygous ATP1A3 mutations in 154 of 187 (82%) AHC patients. Of 34 unique mutations, 31 (91%) are missense, and 16 (47%) had not been previously reported. Concordant with prior studies, more than 2/3 of all mutations are clustered in exons 17 and 18. Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K (26%) and 11 had G937R (8%) mutations. Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus. This study further expands the number and spectrum of ATP1A3 mutations associated with AHC and confirms a more deleterious effect of the E815K mutation on selected neurologic outcomes. However, the complexity of the disorder and the extensive phenotypic variability among subgroups merits caution and emphasizes the need for further studies.
AB - Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase. Published studies to date indicate 2 recurrent mutations, D801N and E815K, and a more severe phenotype in the E815K cohort. We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012. Clinical data were abstracted from standardized caregivers' questionnaires and medical records and confirmed by expert clinicians. We identified ATP1A3 mutations by Sanger and whole genome sequencing, and compared phenotypes within and between 4 groups of subjects, those with D801N, E815K, other ATP1A3 or no ATP1A3 mutations. We identified heterozygous ATP1A3 mutations in 154 of 187 (82%) AHC patients. Of 34 unique mutations, 31 (91%) are missense, and 16 (47%) had not been previously reported. Concordant with prior studies, more than 2/3 of all mutations are clustered in exons 17 and 18. Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K (26%) and 11 had G937R (8%) mutations. Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus. This study further expands the number and spectrum of ATP1A3 mutations associated with AHC and confirms a more deleterious effect of the E815K mutation on selected neurologic outcomes. However, the complexity of the disorder and the extensive phenotypic variability among subgroups merits caution and emphasizes the need for further studies.
UR - https://www.scopus.com/pages/publications/84930656876
U2 - 10.1371/journal.pone.0127045
DO - 10.1371/journal.pone.0127045
M3 - Article
C2 - 25996915
AN - SCOPUS:84930656876
SN - 1932-6203
VL - 10
JO - PLoS ONE
JF - PLoS ONE
IS - 5
M1 - e0127045
ER -